share_log

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

avidity biosciences将于2024年11月12日举行投资者和分析师活动,重点关注Precision Cardiology候选药物,并首次展示下一代科技创新。
PR Newswire ·  10/31 09:00

Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024

Avidity计划在2024年11月16日至18日举行的美国心脏协会(AHA)科学会议上,展示精准心脏病候选者的海报

Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET

投资者和分析师活动系列的第11卷将于2024年11月12日上午8:00通过网络直播提供

SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that the company will share new development candidates from its precision cardiology portfolio and provide a first look at its next-generation technology innovations.

2024年10月31日,美国加利福尼亚州圣地亚哥/PRNewswire/——专注于RNA治疗新型类别称为抗体寡核苷酸结合物(AOCs)的生物制药公司Avidity Biosciences,Inc. (Nasdaq: RNA)今天宣布,该公司将分享其精准心脏病学组合中的新发展候选者,并首次展示其下一代技术创新。

Video Webcast Information
The company is hosting Volume 11 of its investor and analyst event series on November 12, 2024, beginning at 8:00 a.m. ET. The virtual event will be available via a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event.

视频网络直播信息
公司将于2024年11月12日上午8:00开始举办第11卷投资者和分析师活动系列的虚拟活动。这一虚拟活动将通过现场视频网络直播进行,可在Avidity网站的“活动和演示”页面或“投资者”部分中找到。活动结束后,该网络直播的重播将存档在Avidity网站上。

Avidity will be presenting a poster on a lead precision cardiology candidate at the American Heart Association (AHA) Scientific Sessions 2024 on November 16, 2024, at 11:40 a.m. CT in Chicago, Illinois.

Avidity将于2024年11月16日上午11:40在伊利诺伊州芝加哥举行的美国心脏协会(AHA)科学会议上,展示一款主打精准心脏病学候选者的海报。

POSTER PRESENTATION

海报展览

November 16, 2024: 11:40 a.m. - 11:45 a.m. CT

2024年11月16日:上午11:40 - 11:45 美国中部时区

  • Novel Precision Cardiology Treatment for PRKAG2 Cardiomyopathy, a Subset of Patients with Wolff-Parkinson-White Syndrome
  • Novel Precision Cardiology Treatment for PRKAG2 Cardiomyopathy, a Subset of Patients with Wolff-Parkinson-White Syndrome

The poster will be available on the publications page of Avidity's website at .

海报将在Avidity公司网站的出版页面上提供。

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X.

关于Avidity
Avidity Biosciences,Inc.旨在通过提供一种新型的RNA治疗药物——抗体寡核苷酸结合物(AOCs),深刻改善人们的生活。Avidity正在通过其专有的AOCs革新RNA领域,这种技术通过将单克隆抗体的特异性与寡核苷酸治疗的精度相结合,以解决以前存在RNA治疗无法到达的靶位和疾病。利用其专有的AOC平台,Avidity展示了有史以来RNA靶向运输进入肌肉的首次成功,并通过针对三种罕见肌肉疾病的临床开发计划(DM1,DMD和FSHD)领导着该领域。Avidity正在通过内部发现努力,以及关键合作伙伴的共同努力,扩大AOC的范围,包括心脏病学和免疫学。Avidity总部位于加利福尼亚州圣地亚哥。有关我们的AOC平台,临床开发管道和人员的更多信息,请访问我们的网站,并在LinkedIn和X上与我们互动。

Investor Contact:
Mike MacLean
(619) 837-5014
[email protected]

投资者联系人:
Mike MacLean
(619)837-5014
[email protected]

Media Contact:
Navjot Rai
(619) 837-5016
[email protected]

媒体联系人:
Navjot Rai
(619) 837-5016
[email protected]

SOURCE Avidity Biosciences, Inc.

来源:Avidity Biosciences,Inc。

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗?

440k+
440k+

Newsrooms &
新闻发布室&

Influencers
影响力人士
9k+
9k+

Digital Media
数字媒体

Outlets
Outlets
270k+
270k+

Journalists
新闻记者

Opted In
Opted In
GET STARTED
开始使用
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发